STOCK TITAN

Avalo Therapeutics (AVTX) director awarded 40,200 stock options at $17.83 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Avalo Therapeutics director Philip Ron received a grant of stock options covering 40,200 shares of common stock at an exercise price of $17.83 per share. The options vest in three substantially equal annual installments on the first, second and third anniversaries of the June 23, 2026 grant date, contingent on continued board service. Following this award, his reported option holdings from this filing total 40,200 derivative securities.

Positive

  • None.

Negative

  • None.

Insights

Routine director stock option grant with multi-year vesting, neutral signal.

The filing shows Avalo Therapeutics granted director Philip Ron stock options for 40,200 shares at an exercise price of $17.83, expiring on June 23, 2036. This is classified as a grant or award, not an open-market purchase.

The options vest in three substantially equal annual installments over three years, conditioned on continued director service. This structure encourages longer-term alignment with shareholders but is typical for board compensation. No sales or exercises are reported, so the overall signal remains neutral.

Insider Philip Ron M
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 40,200 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 40,200 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 40,200 options Stock Option (Right to Buy) granted June 23, 2026
Exercise price $17.83 per share Exercise price for 40,200 option shares
Shares underlying options 40,200 shares Common Stock underlying granted options
Post-grant derivative holdings 40,200 derivative securities Total options held following transaction
Option expiration June 23, 2036 Expiration date of granted options
Vesting schedule 3 annual installments Vests over three substantially equal annual installments
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 17.8300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock option vests in three substantially equal annual installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Philip Ron M

(Last)(First)(Middle)
C/O AVALO THERAPEUTICS, INC.
1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)
WAYNE PENNSYLVANIA 19087

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$17.8306/23/2026A40,200 (1)06/23/2036Common Stock40,200$040,200D
Explanation of Responses:
1. The stock option vests in three substantially equal annual installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date.
/s/ Christopher Sullivan, Attorney-in-Fact06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Avalo Therapeutics (AVTX) director Philip Ron receive in this Form 4?

Philip Ron received a stock option grant for 40,200 shares of Avalo Therapeutics common stock. The options are a compensation award, not an open-market share purchase, and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the Avalo Therapeutics (AVTX) options granted to Philip Ron?

The stock options granted to Philip Ron have an exercise price of $17.83 per share. This means he can buy Avalo Therapeutics common stock at $17.83 if he exercises the options after they vest and before they expire in 2036.

How do the Avalo Therapeutics (AVTX) options to Philip Ron vest?

The options vest in three substantially equal annual installments on the first, second, and third anniversaries of the grant date. Vesting is conditioned on Ron’s continued service as an eligible director on each vesting date, aligning compensation with ongoing board participation.

When do Philip Ron’s Avalo Therapeutics (AVTX) stock options expire?

The stock options granted to Philip Ron expire on June 23, 2036. He must exercise vested options before this expiration date to acquire Avalo Therapeutics common shares at the fixed $17.83 exercise price, subject to the plan’s and award’s specific terms.

Does this Avalo Therapeutics (AVTX) Form 4 show any stock sales by Philip Ron?

No stock sales are reported in this Form 4. It only shows a grant of 40,200 stock options as a compensation award, with no open-market buying or selling activity disclosed for Avalo Therapeutics shares in the reported transaction data.